Infinity Pharmaceuticals, Inc. INFI
Set alert
0.01 0.00 0.00%
As of Sep 29, 3:59 PM ET
0.0056 Day range 0.01115
52-week range unavailable
- Open
- 0.016
- Prev close
- 0.008
- Mkt cap
- 726.09K
- Vol
- 2.48M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0056
- High
- 0.01115
- Forward P/E
- -0.43
- Beta
- 1.43
- Short ratio
- 1.02
- Inst. own
- 28.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 13, 2023
- 50-d avg
- 0.186
- 200-d avg
- 0.5024
- 1y target
- 0.30
Analyst view
Consensus: hold
Hold
Price target (mean) 0.30
Ratings (0m) 4 1 buy · 3 hold · 0 sell
- Strong buy1
- Buy0
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 3
- 2 months ago 3
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.12 | -0.12 – -0.12 | -0.13 | +7.7% | 700.00K | +2.0% | 1 |
| Next quarter | -0.12 | -0.12 – -0.12 | -0.12 | 0.0% | 700.00K | 0.0% | 1 |
| Current year | -0.46 | -0.46 – -0.46 | -0.50 | +8.0% | 2.70M | +4.1% | 1 |
| Next year | -0.55 | -0.55 – -0.55 | -0.46 | -19.6% | 3.50M | +29.6% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 24, 2023 | Piper Sandler | Downgrade | Overweight | Neutral |
| Nov 16, 2022 | B. Riley Securities | Downgrade | Buy | Neutral |
| May 23, 2022 | Piper Sandler | Maintained | — | Overweight |
| Mar 31, 2022 | Truist Securities | Maintained | — | Buy |
| Mar 30, 2022 | Piper Sandler | Maintained | — | Overweight |
| Oct 18, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 2, 2021 | JP Morgan | Upgrade | Neutral | Overweight |
| Jul 28, 2021 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Mar 18, 2021 | Truist Securities | Initiated | — | Buy |
| Mar 17, 2021 | Wells Fargo | Maintained | — | Equal-Weight |
| Feb 18, 2021 | Piper Sandler | Initiated | — | Overweight |
| Feb 5, 2021 | JP Morgan | Upgrade | Underweight | Neutral |
| May 18, 2020 | B. Riley FBR | Maintained | — | Buy |
| May 12, 2020 | Wells Fargo | Maintained | — | Equal-Weight |
| Mar 4, 2020 | Wells Fargo | Maintained | — | Equal-Weight |
| Jun 27, 2019 | Oppenheimer | Initiated | — | Outperform |
| Jan 4, 2019 | B. Riley FBR | Initiated | — | Buy |
| Nov 12, 2018 | Wells Fargo | Downgrade | Outperform | Market Perform |
| Nov 12, 2018 | JP Morgan | Downgrade | Neutral | Underweight |
| May 31, 2018 | Seaport Global | Initiated | — | Buy |
| Oct 12, 2017 | Wells Fargo | Upgrade | Market Perform | Outperform |
| Jun 15, 2016 | William Blair | Downgrade | Outperform | Market Perform |
| Jun 15, 2016 | Wells Fargo | Downgrade | Outperform | Market Perform |
| Jun 15, 2016 | Jefferies | Downgrade | Buy | Hold |
| Jun 14, 2016 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Jun 14, 2016 | JMP Securities | Downgrade | Outperform | Market Perform |
| Jun 14, 2016 | Wedbush | Upgrade | Underperform | Neutral |
| Mar 22, 2016 | Wedbush | Downgrade | Neutral | Underperform |
| Mar 9, 2016 | JMP Securities | Maintained | — | Market Outperform |
| Mar 2, 2016 | FBR Capital | Initiated | — | Outperform |